Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Interaction between RAAS inhibitors and ACE2 in the context of COVID-19

In the Comment article by Zheng and colleagues (COVID-19 and the cardiovascular system. Nat. Rev. Cardiol. (2020))1, the crucial role of angiotensin-converting enzyme 2 (ACE2) in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, which causes coronavirus disease 2019 (COVID-19), was highlighted. ACE2 is a membrane-bound aminopeptidase that cleaves angiotensin I and angiotensin II into the angiotensin-(1–9) and angiotensin-(1–7) peptides. Several studies support the existence of a cardiovascular-protective ACE2–angiotensin-(1–7)–Mas receptor axis2. ACE2 is overexpressed in heart failure, arterial hypertension and diabetes mellitus3. Moreover, ACE2 has been identified as a functional receptor for the entry of coronaviruses generally, and SARS-CoV-2 specifically, into host cells4.

Given that most of the severe forms of COVID-19 have occurred in elderly patients with cardiovascular comorbidities, Zheng and colleagues speculate about the influence of chronic treatment with blockers of the renin–angiotensin–aldosterone system (RAAS) on the severity of the infection, stating that “ACE2 levels can be increased by the use of renin–angiotensin–aldosterone system inhibitors”1. Consequently, the authors suggest that “the safety and potential effects of antihypertension therapy with ACE inhibitors or angiotensin-receptor blockers in patients with COVID-19 should be carefully considered”.

We wish to clarify that different RAAS inhibitors have different effects on ACE2 levels. By acting at different levels of the system, RAAS inhibitors result in heterogeneous effects on the peptides and enzymes involved. Whereas angiotensin-receptor blockers and mineralocorticoid-receptor blockers have been shown to increase the levels of ACE2 expression and activity in various experimental and clinical models5,6, administration of ACE inhibitors increased cardiac Ace2 mRNA levels but had no effect on ACE2 activity in experimental models7,8. In addition, in an animal model of diabetic nephropathy, the chronic administration of aliskiren (a direct inhibitor of renin) was associated with a reduction in ACE2 expression9. For these reasons, we believe that chronic treatment with ACE inhibitors has no reason to influence the course of SARS-CoV-2 infection. By contrast, the use of angiotensin-receptor blockers or mineralocorticoid-receptor blockers might warrant caution and further analysis in the context of SARS-CoV-2 infection. The reduced expression of ACE2 with aliskiren treatment could be an interesting option in the context of SARS-CoV-2 infection that requires further investigation.

There is a reply to this letter by Zheng, Y. Y. et al. Nat. Rev. Cardiol. (2020).


  1. Zheng, Y. Y., Ma, Y. T., Zhang, J. Y. & Xie, X. COVID-19 and the cardiovascular system. Nat. Rev. Cardiol. (2020).

    Article  PubMed  PubMed Central  Google Scholar 

  2. Patel, V. B., Zhong, J. C., Grant, M. B. & Oudit, G. Y. Role of the ACE2/angiotensin 1–7 axis of the renin–angiotensin system in heart failure. Circ. Res. 118, 1313–1326 (2016).

    CAS  Article  Google Scholar 

  3. Te Riet, L., van Esch, J. H., Roks, A. J., van den Meiracker, A. H. & Danser, A. H. Hypertension: renin–angiotensin–aldosterone system alterations. Circ. Res. 116, 960–975 (2015).

    Article  Google Scholar 

  4. Hoffmann, M. et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell (2020).

    Article  PubMed  PubMed Central  Google Scholar 

  5. Keidar, S. et al. Mineralocorticoid receptor blocker increases angiotensin-converting enzyme 2 activity in congestive heart failure patients. Circ. Res. 97, 946–953 (2005).

    CAS  Article  Google Scholar 

  6. Zhong, J. C. et al. Telmisartan attenuates aortic hypertrophy in hypertensive rats by the modulation of ACE2 and profilin-1 expression. Regul. Pept. 166, 90–97 (2011).

    CAS  Article  Google Scholar 

  7. Ferrario, C. M. et al. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation 111, 2605–2610 (2005).

    CAS  Article  Google Scholar 

  8. Tipnis, S. R. et al. A human homolog of angiotensin-converting enzyme: cloning and functional expression as a captopril-insensitive carboxypeptidase. J. Biol. Chem. 275, 33238–33243 (2000).

    CAS  Article  Google Scholar 

  9. Ding, W. et al. Aliskiren inhibits angiotensin II/angiotensin 1–7 (Ang II/Ang1–7) signal pathway in rats with diabetic nephropathy [Chinese]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 34, 891–895 (2018).

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations


Corresponding author

Correspondence to Jean-Jacques Mourad.

Ethics declarations

Competing interests

J.-J.M. has received fees for consultancy from Mylan, Pfizer and Servier. B.I.L. has received grants and personal fees from Bayer, Roche and Servier.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Mourad, JJ., Levy, B.I. Interaction between RAAS inhibitors and ACE2 in the context of COVID-19. Nat Rev Cardiol 17, 313 (2020).

Download citation

  • Published:

  • Issue Date:

  • DOI:

Further reading


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing